The medicine (Trimetazidine) is commonly used as an add-on therapy for adult patients managing symptoms related to Chronic Stable Angina Pectoris, which generally may be part of symptomatic management when initial, first-line antianginal therapies have proven insufficient in providing adequate symptom control or when the patient is intolerant to those agents. This therapeutic approach serves as a means for symptom relief.

This treatment is primarily applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning, particularly the limitation imposed by reduced physical effort tolerance. Key therapeutic areas of use include managing the recurring symptom clusters of chest tightness, pressure, and heaviness that are often triggered by physical activity. A main benefit is that it helps to ease the overall symptom load by supporting a reduction in the frequency and intensity of anginal attacks.

Quick Note: Symptomatic Support This medication may assist with easing symptoms linked to functional stress, which is relevant when physical demand occurs.

Who can and cannot use Vastarel — official regulatory information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult patients (aged 18 years and older) with Chronic Stable Angina Pectoris.
Populations for whom use is not recommended	Children and adolescents (under 18 years of age). Pregnant women and breastfeeding women.
Populations for whom use is contraindicated	Patients with known hypersensitivity. Patients with Parkinson’s disease, Parkinsonian symptoms, tremors, restless leg syndrome, or related movement disorders.

Condition-Based Rules and Restrictions

Category	Official Regulatory Classification
Severe Renal Impairment	Absolute Contraindication (Creatinine clearance less than 30 ml/min).
Moderate Renal Impairment	Conditional Use/Restriction (Creatinine clearance in the range 30 - 60 ml/min), requiring a lower dose.
Age-Related Eligibility	Approved for adults (18+). Older adults (75 years and older) require caution due to potential decreased renal function.

Official Eligibility Statements

• Vastarel is contraindicated in patients with any diagnosis of movement disorders, including Parkinson’s disease and Restless Leg Syndrome.
• The medicine is absolutely contraindicated in patients with severe renal impairment.
• Use is not recommended for the entire pediatric population (under 18 years) as safety and efficacy have not been established.
• Use is not recommended during pregnancy or while breastfeeding due to the absence of sufficient clinical data.

Connection to the Overall Eligibility Profile

Official regulatory documents establish a strict eligibility profile, limiting use to adult patients while formally prohibiting the drug for anyone with movement disorders or severe kidney dysfunction. Use in all pediatric, pregnant, and breastfeeding populations is systematically not recommended.

Interactions with other medicines and products

Official regulatory documents consistently state that no drug interactions have been identified for the active ingredient, Trimetazidine dihydrochloride (Vastarel), with commonly used co-administered medicines.

This lack of identified interaction risk means the regulatory labeling for Vastarel does not impose restrictions related to co-administration with many common cardiovascular agents. These include, but are not limited to:

• Antianginal and Cardiovascular Medicines: Beta-blockers, calcium antagonists, and nitrates.
• Other Agents: Oral anticoagulants, heparin, hypolipidemic agents, and salicylic acid.

Consequently, no medicinal products are officially classified as contraindicated due to a drug-drug interaction risk. Furthermore, there are no documented instructions for timing separation, such as administering doses several hours apart, nor are there any explicitly documented interactions with food, alcohol, or herbal products in the product’s official prescribing information.

Interaction Type	Official Regulatory Statement
Drug-Drug Interactions	No drug interactions have been identified
Metabolic Interactions	Not cited as an inhibitor or inducer of drug hydroxylation

Population-Dependent Pharmacokinetic Caution

The regulatory label does note a pharmacokinetic caution regarding the drug's exposure, which is not an interaction with another substance but a function of patient clearance:

• Increased Exposure Risk: Caution is advised when prescribing to elderly patients (over 75 years of age) and patients with moderate renal impairment ( CrCl 30-60 mL/min), as an increase in Trimetazidine exposure is expected in these populations.

Shifting the Myocardial Energy Source

This mechanism focuses on Long-Chain 3-Ketoacyl-CoA Thiolase ( LC 3-KAT) enzyme inhibition, which modulates the heart muscle's primary energy pathway. By inhibiting fatty acid oxidation, the mechanism promotes increased utilization of glucose oxidation. This metabolic shift alters the oxygen cost of energy generation, resulting in an increase in the oxygen efficiency of ATP synthesis at the cellular level.

---

Modulation of Cellular Homeostasis

The resulting ATP concentration stability supports the function of vital ionic pumps ( Na^+/ K^+- ATPase) under oxygen-restricted conditions. This action modulates ionic pump activity, which influences intracellular acidosis and calcium ion accumulation, supporting the cell's ability to maintain ionic homeostasis.

---

Haemodynamic Neutrality

The described mechanism is characterized by its metabolic modulation and haemodynamic neutrality. The effect operates solely through cellular energy pathways within the mitochondria, without interacting with the receptors or mediators that regulate major circulatory parameters. Consequently, the mechanism maintains the existing heart rate and blood pressure**.

How to Use Vastarel (Trimetazidine)

The administration of Trimetazidine is strictly by the oral route and is intended for use in a maintenance setting, not for the initial treatment of acute episodes such as unstable angina or myocardial infarction. The dosage regimen varies based on the formulation, which includes the immediate-release (IR) 20 mg tablet and the modified-release (MR) 35 mg tablet.

Standard Dosing and Administration

The medicine must be taken during meals. The standard adult dosing patterns are:

• 35 mg Modified-Release (MR) Tablet: One tablet (35 mg) is taken twice daily, resulting in a total daily dose of 70 mg.
• 20 mg Immediate-Release (IR) Tablet: One tablet (20 mg) is taken three times a day, resulting in a total daily dose of 60 mg.

Modified-Release tablets must be swallowed whole and must not be broken, crushed, or chewed, as this compromises the intended sustained release of the active ingredient.

Population-Specific Adjustments

Dosage adjustments are required for patients with moderate renal impairment. In patients with a creatinine clearance between 30 and 60 mL/min, the dosage must be reduced. For the 35 mg MR form, the recommended dose is one tablet (35 mg) once daily, taken in the morning during breakfast. For the 20 mg IR form, the recommended dose is 20 mg twice daily. Dose titration in older adults (aged over 75) should be exercised with caution. The use of Trimetazidine is not recommended for children under 18 years of age because safety and efficacy have not been established in this population.

Treatment Duration and Review

The benefit of the treatment must be formally assessed after three months of use. If no objective treatment response is determined at this time, the treatment should be discontinued.

Evidence for use in Chronic Stable Angina Pectoris

Clinical research for Trimetazidine has been evaluated in patients managing Chronic Stable Angina Pectoris. This medicine was evaluated in research exploring its use as an add-on treatment for adults who continued to experience symptoms despite using standard first-line therapies. Researchers utilized randomized, controlled, double-blind trials (RCTs) and systematic reviews to observe patient groups. The studies explored outcomes related to symptom intensity and physical capacity, tracking changes in weekly anginal attacks and reliance on short-acting emergency nitrates. Research also examined functional capacity using exercise tolerance tests, which reported how symptoms evolved under stress and measured physical outcomes.

---

Long-term Research and Study Gaps

Beyond the initial short-term trials (typically 2 to 3 months), large observational studies explored sustained effects and monitored patterns related to major health events over periods that could extend up to five years. Research has explored whether observed improvements in exercise tolerance may be sustained. Findings regarding long-term clinical outcomes, such as major adverse cardiovascular events (MACE), were mixed, and certainty remains low regarding the medicine's role in altering these outcomes. The follow-up durations for many efficacy trials were limited, resulting in limited information for long-term outcomes that require many years of observation.

---

Studies in Specific Patient Groups

Trimetazidine was evaluated in specific patient populations, including studies examining the experience of older adults and people with co-existing conditions, particularly those with diabetes. These studies monitored functional outcomes and described patterns related to cardiac function and systemic balance in these groups. Research findings help contextualize how patients with complex medical backgrounds reported their experience, but results apply only to the populations studied in these specific trials. Data for other groups, such as pregnant or pediatric populations, remain insufficient.

Key Studies & References

1. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis
2. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized control trials

Common questions about Vastarel (FAQ)

Q: What is the active ingredient in Vastarel?

The active ingredient in Vastarel is Trimetazidine dihydrochloride. According to the official product information, this substance is intended to support the heart muscle under conditions of low oxygen supply.

Q: What types of heart conditions is Vastarel used for?

Regulatory documents state that Vastarel is indicated as an add-on treatment for stable angina pectoris, a condition that causes chest pain. It is intended for adult patients whose condition is not adequately controlled by or who are intolerant to first-line anti-anginal therapies.

Q: Can Vastarel be used to treat dizziness or ringing in the ears?

The current official product information does not list the treatment of dizziness (vertigo) or ringing in the ears (tinnitus) as an approved indication for Vastarel. While the active ingredient has been studied for these uses in the past, its current authorized use is solely for stable angina pectoris in adults.

Q: Does Vastarel cure heart disease?

Official information indicates that Vastarel is an add-on therapy for stable angina pectoris. Its role is to help manage symptoms, and it is not a cure for the underlying disease. It is meant to support the heart cells when they receive less oxygen.

Q: How long does it take for Vastarel to start working?

Vastarel is primarily intended for long-term, sustained management of stable angina pectoris. It is not an acute-relief medication, and consistent use as prescribed is necessary to maintain its effects. Official information advises continued treatment for full benefit.

Q: What should I do if I miss a dose of Vastarel?

If a dose is missed, regulatory sources advise that you should continue with the next scheduled dose at the usual time. It is specifically stated that you should not take a double dose to compensate for the one you missed. Always rely on the specific guidance in the patient information leaflet.

Q: Is it safe to stop taking Vastarel suddenly?

Vastarel is typically prescribed as a long-term treatment for a chronic condition. Official documents state that patients must not stop taking it without consulting their healthcare provider. Any decision to alter or discontinue treatment should be made under medical supervision.

Official Storage and Disposal Requirements

Storing Vastarel (Trimetazidine) correctly is defined by official regulatory requirements to maintain product stability and ensure public safety. The primary storage constraint is temperature, which mandates that the tablets not be stored above 30 C.

Mandatory Constraints

Constraint Area	Official Regulatory Statement
Temperature Limit	Store at or below 30 C.
Child Protection	Must be kept out of the sight and reach of children.
Packaging	Do not use the medicine after the expiry date shown on the packaging.

Official Disposal Rules

Disposal must adhere to pharmaceutical waste guidelines. It is strictly prohibited to throw away unused or expired medicine via wastewater or ordinary household waste. Instead, regulatory labeling instructs the user to ask a pharmacist for the approved local method of disposal for pharmaceutical products.